On April 10, 2023 CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, reported that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees’ acceptance of employment with the company (Press release, CTI BioPharma, APR 10, 2023, View Source [SID1234629902]). The equity awards were approved on April 10, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The employees received options to purchase an aggregate of 36,000 shares of CTI BioPharma common stock. The options will be issued upon each employee’s grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

On April 10, 2023 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported that  the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 311,700 shares of its common stock to 15 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan") (Press release, Crinetics Pharmaceuticals, APR 10, 2023, View Source [SID1234629900]). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $16.02 per share, which is equal to the closing price of Crinetics’ common stock on The Nasdaq Global Select Market on April 10, 2023. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

On April 10, 2023 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023 (Press release, Aptose Biosciences, APR 10, 2023, View Source [SID1234629899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Aptose management team will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, or to access the panel presentation, please contact your Canaccord Genuity conference representative.

Canaccord Genuity’s Horizons in Oncology Conference

Panel Title: New & Better Approaches for Oncology Targets
Date: Thursday, April 20, 2023
Presentation Time: 2:00 – 2:45 PM
Format: Panel presentation moderated by John Newman, Ph.D., Biotechnolgy Analyst
Participant: Dr. William Rice, Chairman, President and Chief Executive Officer, Aptose

On April 10, 2023 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) taking place from May 16-20, 2023 in Los Angeles, CA (Press release, Abeona Therapeutics, APR 10, 2023, View Source [SID1234629898]). Accepted abstracts include new data on three internally developed investigational preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program, including ABO-504 for Stargardt disease, ABO-503 for X-linked retinoschisis (XLRS) and ABO-505 for autosomal dominant optic atrophy (ADOA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ASGCT (Free ASGCT Whitepaper), the data we present will highlight the potential of our proprietary AAV capsids and gene constructs to express recombinant protein in target eye tissues and rescue mutant phenotypes," said Brian Kevany, Ph.D., Chief Technical Officer and Head of Research at Abeona. "We have started to submit pre-IND meeting requests to the FDA for our gene therapy product candidates and anticipate meetings to take place in the second quarter of 2023. We are excited for the opportunity to share our new data with the scientific community at ASGCT (Free ASGCT Whitepaper)."

Details for the poster presentations are as follows:

Abstract Title: In Vivo Production of Full-Length ABCA4 Protein Following Cre-Mediated Recombination from Dual AAV Vectors in ABCA4-/- Mice
Presenter: Dr. Paul Wille, Director, Product Development, Abeona Therapeutics
Session Date/Time: Wednesday, May 17, 2023 at 12:00 PM PT
Abstract number: 715

Abstract Title: ABO-503, a Novel Gene Therapy for Treatment of X-Linked Retinoschisis
Presenter: Dr. Joseph Fogerty, Senior Scientist, Product Development, Abeona Therapeutics
Session Date/Time: Thursday, May 18, 2023 at 12:00 PM PT
Abstract number: 1131

Abstract Title: AAV Gene Therapy for Autosomal Dominant Optic Atrophy Caused by Mutation in the Opa1 Gene
Presenter: Dr. Rachel Stupay, Senior Scientist, Product Development, Abeona Therapeutics
Session Date/Time: Friday, May 19, 2023 at 12:00 PM PT
Abstract number: 1478

On April 9, 2023 Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, reported that it will be exhibiting and presenting a poster at the AACR (Free AACR Whitepaper) Annual Meeting 2023 in Orlando, FL. Syncell’s Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification (Press release, Syncell, APR 9, 2023, View Source [SID1234629896]). Syncell announces that Microscoop Mint, the first commercial Microscoop platform of Syncell, will be available for order. Earlier this year, Syncell also announced expansion of its Global Rapid Access Service Program (GRASP) to use Microscoop.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Total-Sync Ultra-Content Microscopic Opto-Biotinylation Enables High-Sensitivity Hypothesis-Free Subcellular Protein Discovery"

Tweet this
"Syncell’s Microscoop technology is not really a spatial proteomic mapping technology, it is a direct spatial proteomic discovery technology to help researchers identify novel protein biomarkers. We are excited to see the high demands of services for diverse life science problems. We are happy to see recent successful proteomic discovery for customers’ research projects. We believe Microscoop technology will also be broadly useful for cancer research," said Dr. JC Liao, the Founder and CEO of Syncell.

Details of the technology and the new product will be showcased at Syncell’s exhibit hall booth (#129). A poster will be presented on April 18, 2023 @ 1:30 PM – 5:00 PM at Section 23 titled "Total-Sync Ultra-Content Microscopic Opto-Biotinylation Enables High-Sensitivity Hypothesis-Free Subcellular Protein Discovery". Copies of the poster will also be available at the booth.